General effect of low-dose tamsulosin (0.2 mg) as a first-line treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia: a systematic review and meta-analysis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Shim, Sung Ryul | - |
dc.contributor.author | Kim, Jae Heon | - |
dc.contributor.author | Choi, Hoon | - |
dc.contributor.author | Lee, Won Jin | - |
dc.contributor.author | Kim, Hae Joon | - |
dc.contributor.author | Bae, Min Young | - |
dc.contributor.author | Hwang, Sung Dong | - |
dc.contributor.author | Kim, Khae Hwan | - |
dc.contributor.author | Bae, Jae Hyun | - |
dc.contributor.author | Yoon, Sang Jin | - |
dc.date.accessioned | 2021-09-04T19:30:07Z | - |
dc.date.available | 2021-09-04T19:30:07Z | - |
dc.date.created | 2021-06-15 | - |
dc.date.issued | 2015-02 | - |
dc.identifier.issn | 0300-7995 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/94460 | - |
dc.description.abstract | Purpose: In Asian countries, low-dose tamsulosin (0.2 mg) is used widely but this dose has been less popular than 0.4 mg tamsulosin or other types of alpha blockers. The aim of this study was to investigate the efficacy and safety of low-dose tamsulosin by systematic review and meta-analysis. Methods: We conducted a meta-analysis of improvements of lower urinary tract symptoms using International Prostate Symptom Score (IPSS), maximal urinary flow rate (Qmax), post-voided residual volume (PVR), and quality of life (QOL). Relevant studies were found using MEDLINE, Embase, and the Cochrane library. Final inclusion was determined by randomized controlled trials (RCT) and performance of IPSS. Results: A total of fourteen studies were included, with a total sample size of 2147 subjects (1044 experimental and 1103 controls). Study durations ranged from 4 to 52 weeks. The mean change of IPSS improvement from baseline for tamsulosin was -7.18 (95% CI: -7.83, -6.54). The mean change of QOL improvement from baseline was -1.34 (95% CI: -1.46, -1.22). The overall Qmax improvement from baseline was 2.32 ml/sec (95% CI: 1.95, 2.70). The mean change of PVR improvement from baseline was -11.12 ml (95% CI: -17.61, -4.64). Regarding safety, four studies did not report any adverse events while others reported that adverse events were all tolerated. Conclusions: Although this study did not consider placebo effect and has high IPSS baseline scores, this study clarifies that low-dose tamsulosin has generally positive effect and safety in treatment of LUTS and could be a suitable option as an initial treatment, especially for patients with low body mass index, as is typical of Asian people. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | TAYLOR & FRANCIS LTD | - |
dc.subject | ALPHA-BLOCKER | - |
dc.subject | SEVERE HYPOTENSION | - |
dc.subject | EFFICACY | - |
dc.subject | MULTICENTER | - |
dc.subject | SAFETY | - |
dc.subject | ANTAGONIST | - |
dc.subject | TERAZOSIN | - |
dc.subject | MEN | - |
dc.subject | NAFTOPIDIL | - |
dc.subject | SILODOSIN | - |
dc.title | General effect of low-dose tamsulosin (0.2 mg) as a first-line treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia: a systematic review and meta-analysis | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Choi, Hoon | - |
dc.contributor.affiliatedAuthor | Lee, Won Jin | - |
dc.contributor.affiliatedAuthor | Kim, Hae Joon | - |
dc.contributor.affiliatedAuthor | Bae, Jae Hyun | - |
dc.identifier.doi | 10.1185/03007995.2014.980887 | - |
dc.identifier.scopusid | 2-s2.0-84923380787 | - |
dc.identifier.wosid | 000349979800020 | - |
dc.identifier.bibliographicCitation | CURRENT MEDICAL RESEARCH AND OPINION, v.31, no.2, pp.353 - 365 | - |
dc.relation.isPartOf | CURRENT MEDICAL RESEARCH AND OPINION | - |
dc.citation.title | CURRENT MEDICAL RESEARCH AND OPINION | - |
dc.citation.volume | 31 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 353 | - |
dc.citation.endPage | 365 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalResearchArea | Research & Experimental Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.relation.journalWebOfScienceCategory | Medicine, Research & Experimental | - |
dc.subject.keywordPlus | ALPHA-BLOCKER | - |
dc.subject.keywordPlus | SEVERE HYPOTENSION | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | MULTICENTER | - |
dc.subject.keywordPlus | SAFETY | - |
dc.subject.keywordPlus | ANTAGONIST | - |
dc.subject.keywordPlus | TERAZOSIN | - |
dc.subject.keywordPlus | MEN | - |
dc.subject.keywordPlus | NAFTOPIDIL | - |
dc.subject.keywordPlus | SILODOSIN | - |
dc.subject.keywordAuthor | Alpha blockers | - |
dc.subject.keywordAuthor | Prostatic hyperplasia | - |
dc.subject.keywordAuthor | Tamsulosin | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.